| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-03-11 | Prokarium (UK) the University of Birmingham’s Institute of Microbiology and Infection (UK) | £0.4m | grant | Technology Strategy Board (UK) Biotechnology and Biological Sciences Research Council (BBSRC) (UK) | Infectious diseases | Grant |
| 2013-03-11 | Progenitor Labs (UK) | £ 4 million | financing round | SR One (UK) | Technology - Services | Financing round |
| 2013-03-06 | Active Biotech (Sweden) | SEK 270 million (€ 32.5 million) | private placement | Investor AB (Sweden) | Autoimmune diseases – Inflammatory diseases - Cancer - Oncology - Neurodegenerative diseases | Private placement |
| 2013-02-28 | Ablynx (Belgium) | €31.5 million | private placement | domestic and international institutional investors, qualified institutional buyers in the United States | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Cancer - Oncology - Infectious diseases | Private placement |
| 2013-02-28 | Dezima Pharma (The Netherlands) | €14.2 million | loan, series A financing round | Agentschap NL (The Netherlands) BioGeneration Ventures (The Netherlands) Forbion Capital Partners (The Netherlands) New Science Ventures (USA) | Cardiovascular diseases - Metabolic diseases | Fundraising |
| 2013-02-27 | EpiTherapeutics (Denmark) | € 5 million | series A financing round | Novo Seeds (Denmark) SEED Capital Denmark (Denmark) Lundbeckfond Emerge (Denmark) Merck Serono Ventures (Germany - Switzerland) | Cancer - Oncology | Fundraising |
| 2013-02-27 | Mission Therapeutics (UK) | grant | BioMedical Catalyst Fund (UK) | Cancer - Oncology | Grant | |
| 2013-02-25 | Biocartis (Belgium) | € 1.9 million | grant | Flemish agency for Innovation by Science and Technology (IWT) (Belgium) | Grant | |
| 2013-02-15 | Molmed (Italy) | €4,999,999.00 | capital increase | Fininvest (Italy) H-Equity (Italy) H-Invest (Italy) | Cancer - Oncology | Capital increase |
| 2013-02-15 | Neovacs (France) | €6.3 million | private placement | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Private placement | |
| 2013-02-14 | Domainex (UK) | £1.5m | financing round | Longbow Capital (UK) Bury Fitzwilliam-Lay and Partners (UK) University College London Business (UCLB - UK) | Cancer - Oncology - Inflammatory diseases - Immunological diseases | Fundraising |
| 2013-02-11 | e-Therapeutics (UK) | £40 million (€47.3 million) | private placement | Cancer - Oncology | Private placement | |
| 2013-02-11 | Piqur Therapeutics (Switzerland) | seed financing | Cancer - Oncology | Fundraising | ||
| 2013-02-07 | Flamel Technologies (France) | $15 million (€11.2 million) | debt financing | Deerfield Management (USA) | Establishment of a new subsidiary in the EU | |
| 2013-02-05 | Ability Pharmaceuticals (Spain) | € 1.2 million | grant | INNPACTO-2012 Collaborative Program (Spain) | Cancer - Oncology | Grant |
| 2013-02-01 | Antabio (France) | €4.7 million | grant | Wellcome Trust (UK) | Infectious diseases | Grant |
| 2013-01-31 | Verona Pharma (UK) | £1.1m and £5.0m | private placement, equity financing | Darwin Strategic Limited (UK) | Allergic diseases - Inflammatory diseases - Respiratory diseases | Private placement |
| 2013-01-31 | BIOSID consortium (Ceed (France), Defymed (France), AvantiCell (UK), the Department of Endocrinology, Diabetes and Nutrition from the Montpellier UHC(France), the Nuffield department of Surgical Sciences of the Oxford University (UK),Endocells (France), the laboratory of Experimental Surgery of the Catholic University of Louvain (UCL) (Belgium) | € 5.5 million | grant | European Commission’s Seventh Framework Program (FP7) | Metabolic diseases | Grant |
| 2013-01-30 | Galapagos (Belgium) | €2.5 million | grant | Flemish agency for Innovation by Science and Technology (IWT) (Belgium) | Allergic diseases - Inflammatory diseases - Digestive diseases | Grant |
| 2013-01-29 | Zytoprotec (Austria) | € 4 million | series A financing round | Baxter Ventures (USA) | Fundraising |
